SEOUL, Aug. 24 (Korea Bizwire) — SK bioscience Co. said Thursday it has reached a deal with Vaxxas, an Australian biotechnology company, to jointly develop a new patch-type typhoid vaccine. The global charitable foundation Wellcome will fund the collaboration for the first two years, awarding US$3.67 million to conduct the first-phase clinical trial, according to [...]
SEOUL, Aug. 23 (Korea Bizwire) — SK bioscience Co., a pharmaceutical affiliate under South Korea’s SK Group, said Wednesday it will produce 5 million doses of its signature cell-based influenza vaccine SKYCellflu nationwide from next month for the coming winter season. It resumed the production two years after it had stopped manufacturing the prefilled syringe-typed [...]
SEOUL, Aug. 9 (Korea Bizwire) – SK bioscience Co., a pharmaceutical affiliate under South Korea’s SK Group, said Wednesday it has purchased 6.5 million shares in the U.S.-based biotechnology company Novavax Inc. for 110 billion won (US$83.4 million). With the stock purchase, SK bioscience will hold a 6.5 percent share in Novavax, according to the [...]
SEOUL, July 5 (Korea Bizwire) — SK bioscience Co., a pharmaceutical affiliate of South Korea’s SK Group, said Wednesday it has joined hands with Thailand’s state-run drugmaker to build vaccine manufacturing and development infrastructure in the Southeast Asian country. SK bioscience and Thailand’s Government Pharmaceutical Organization (GPO) signed a memorandum of understanding (MOU) on Tuesday, [...]
SEOUL, May 30 (Korea Bizwire) — SK bioscience Co., a pharmaceutical affiliate of South Korea’s SK Group, said Tuesday its COVID-19 vaccine SKYCovione has won approval from British authorities. The British Medicines and Healthcare products Regulatory Agency has approved the Korean vaccine for use as a primary vaccination in those aged 18 and over in [...]
SEOUL, April 28 (Korea Bizwire) — SK Bioscience Co., a pharmaceutical affiliate under SK Group, said Friday it will invest 2.4 trillion won (US$1.79 billion) by 2028 as it is seeking to further expand its contract manufacturing business. The proposed investment — twice the amount the company had spent in the past five years — [...]
SEOUL, Oct. 25 (Korea Bizwire) — South Korean drugmaker SK Bioscience Co. said Tuesday it has signed a deal to join hands with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop messenger RNA (mRNA) vaccines. Under the agreement, SK Bioscience will receive US$140 million for the project from CEPI, an Oslo-based international public-private partnership, [...]
SEOUL, Sept. 2 (Korea Bizwire) — SKYCovione, South Korea’s first homegrown COVID-19 vaccine developed by SK Bioscience Co., has been proven to be effective against coronavirus omicron subvariants when administered as a booster shot, a state-run research center said Friday. The Center for Infectious Disease Research (CIDR) said it has confirmed through research SKYCovione’s efficacy [...]
SEOUL, June 29 (Korea Bizwire) — South Korea on Wednesday approved the use of SKYCovione, the country’s first homegrown COVID-19 vaccine developed by SK Bioscience Co., taking a major step toward achieving vaccine sovereignty in the fight against the pandemic. The Ministry of Food and Drug Safety (MFDS) said it approved the use of SKYCovione, [...]
SEOUL, June 27 (Korea Bizwire) — South Korea’s first COVID-19 vaccine candidate, developed by SK Bioscience Co., has received an approval recommendation from a government advisory group of pharmaceutical experts, officials said Monday, pushing the vaccine candidate one step closer to commercial launch. The Ministry of Food and Drug Safety said GBP510, the vaccine candidate [...]